Court finds Teva does not infringe Corcept's Korlym patents; Corcept plans appeal

CORCEPT THERAPEUTICS INC

District of New Jersey ruled Teva does not infringe Corcept's U.S. Patents 10,195,214 and 10,842,800.
Patents cover methods of safely administering Korlym with strong CYP3A4 inhibitors.
CEO Joseph Belanoff called decision disappointing and based on legal and factual errors.
Corcept will pursue a vigorous appeal; believes patents expanded treatment options for Cushing's syndrome.
FDA had added the patented methods to Korlym's prescribing instructions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.